Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score ( mCCS )-Reference-Cited by-同舟云学术

Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score ( mCCS )

Published:2019-03-18 Issue:7 Volume:21 Page:816-826
ISSN:1462-8910
Container-title:Colorectal Disease
language:en
Short-container-title:Colorectal Dis

Author:

Marschner N.¹^ORCID,Frank M.²,Vach W.³,Ladda E.⁴,Karcher A.⁵,Winter S.⁶,Jänicke M.⁶,Trarbach T.⁷

Affiliation:

1. Praxis für interdisziplinäre Onkologie und Hämatologie Freiburg Germany

2. Biostatistics iOMEDICO Freiburg Germany

3. Department of Orthopaedics and Traumatology Universitätsspital Basel Basel Switzerland

4. Onkologische Schwerpunktpraxis Neumarkt Neumarkt in der Oberpfalz Germany

5. Onkologische Schwerpunktpraxis Heidelberg Germany

6. Clinical Epidemiology and Health Economics iOMEDICO Freiburg Germany

7. MVZ des Klinikums Wilhelmshaven Wilhelmshaven Germany

Funder

Pfizer

Amgen

Bayer

Publisher

Wiley

Subject

Gastroenterology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/codi.14600

Reference26 articles.

1. Robert Koch‐Institut Gesellschaft der epidemiologischen Krebsregister in Deutschlande.V. editors. Krebs in Deutschland 2013/2014. Häufigkeiten und Trends [Internet]. 11. Ausgabe.Berlin:Robert Koch‐Institut;2017. Available from:https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/krebs_in_deutschland_2017.pdf?__blob=publicationFile

2. Metastatic Colorectal Cancer: Current State and Future Directions

3. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

4. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

5. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis;ESMO Real World Data and Digital Oncology;2024-06

2. FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world;International Journal of Cancer;2022-09-22

3. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary;International Journal of Cancer;2020-06

4. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer;JAMA Network Open;2020-03-10